Harmonization of outcomes in epidermolysis bullosa: report of the Core Outcome Sets for Epidermolysis Bullosa (COSEB) kick-off meeting.

Competing Interests: Conflicts of interest P.I.S. receives departmental independent research grants for the TREAT NL registry from Pharma starting in December 2019, is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of, for example, psoriasis and atopic dermatitis, for which financial compensation is paid to the department/hospital, and is Chief Investigator for the Systemic and Phototherapy Atopic Eczema Registry (TREAT NL) for adults and children. She participated in the development of one of the HOME core outcome instruments (Recap of atopic eczema, RECAP), and in the development of the Outcome Measures for VAscular Malformations (OVAMA) questionnaire for vascular malformations. D.K. has served as a consultant for Amryt Pharma, Fibrx Inc. and Rheacell GmbH and is co-founder of Crowd Pharma, a company focusing on repurposing losartan for EB. V.W. acts as consultant for and holds shares of Diaderm GmbH. M.C.B. has served on the advisory boards of Amryt Pharma and Krystal Biotech Inc. E.W.H.K., P.C.v.d.A., M.L., A.M.G.P., R.R., E.V. and T.W. declare that they have no conflicts of interest regarding the scope of this work.